-
1 Comment
AtriCure, Inc is currently in a long term uptrend where the price is trading 38.8% above its 200 day moving average.
From a valuation standpoint, the stock is 99.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 13.3.
AtriCure, Inc's total revenue sank by 5.9% to $58M since the same quarter in the previous year.
Its net income has dropped by 15.3% to $-19M since the same quarter in the previous year.
Finally, its free cash flow grew by 136.8% to $3M since the same quarter in the previous year.
Based on the above factors, AtriCure, Inc gets an overall score of 3/5.
Exchange | F |
---|---|
CurrencyCode | EUR |
ISIN | None |
Industry | |
Sector |
Dividend Yield | 0.0% |
---|---|
Beta | 1.36 |
Market Cap | 3B |
PE Ratio | 58.11 |
Target Price | 96.71 |
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. It offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. The company also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used to treat symptomatic persistent and long-standing persistent atrial fibrillation patients; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, it sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; COBRA Fusion Surgical Ablation System; Fusion Magnetic Retriever System; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. The company markets and sells its products through independent distributors and direct sales personnel. AtriCure, Inc. was incorporated in 2000 and is headquartered in Mason, Ohio.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for A5I.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025